243 related articles for article (PubMed ID: 35315858)
21. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz.
Avachat AM; Parpani SS
Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986
[TBL] [Abstract][Full Text] [Related]
22. Lyotropic liquid crystalline phases: Drug delivery and biomedical applications.
Chavda VP; Dyawanapelly S; Dawre S; Ferreira-Faria I; Bezbaruah R; Rani Gogoi N; Kolimi P; Dave DJ; Paiva-Santos AC; Vora LK
Int J Pharm; 2023 Nov; 647():123546. PubMed ID: 37884213
[TBL] [Abstract][Full Text] [Related]
23. PEGylation of phytantriol-based lyotropic liquid crystalline particles--the effect of lipid composition, PEG chain length, and temperature on the internal nanostructure.
Nilsson C; Østergaard J; Larsen SW; Larsen C; Urtti A; Yaghmur A
Langmuir; 2014 Jun; 30(22):6398-407. PubMed ID: 24833115
[TBL] [Abstract][Full Text] [Related]
24. Size-Dependent Encapsulation and Release of dsDNA from Cationic Lyotropic Liquid Crystalline Cubic Phases.
Sarkar S; Tran N; Soni SK; Conn CE; Drummond CJ
ACS Biomater Sci Eng; 2020 Aug; 6(8):4401-4413. PubMed ID: 33455184
[TBL] [Abstract][Full Text] [Related]
25. A Versatile Nanocarrier-Cubosomes, Characterization, and Applications.
Oliveira C; Ferreira CJO; Sousa M; Paris JL; Gaspar R; Silva BFB; Teixeira JA; Ferreira-Santos P; Botelho CM
Nanomaterials (Basel); 2022 Jun; 12(13):. PubMed ID: 35808060
[TBL] [Abstract][Full Text] [Related]
26. Cubosomes: an overview.
Garg G; Saraf S; Saraf S
Biol Pharm Bull; 2007 Feb; 30(2):350-3. PubMed ID: 17268078
[TBL] [Abstract][Full Text] [Related]
27. Cell interactions with lipid nanoparticles possessing different internal nanostructures: Liposomes, bicontinuous cubosomes, hexosomes, and discontinuous micellar cubosomes.
Yap SL; Yu H; Li S; Drummond CJ; Conn CE; Tran N
J Colloid Interface Sci; 2024 Feb; 656():409-423. PubMed ID: 38000253
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo FESEM).
Rizwan SB; Dong YD; Boyd BJ; Rades T; Hook S
Micron; 2007; 38(5):478-85. PubMed ID: 17011783
[TBL] [Abstract][Full Text] [Related]
29. Cubosomes as Carriers for MRI Contrast Agents.
Alcaraz N; Boyd BJ
Curr Med Chem; 2017; 24(5):470-482. PubMed ID: 27538694
[TBL] [Abstract][Full Text] [Related]
30. Nanostructured cubosomes as a platform for oral drug delivery.
Liu M; Chen M; Xu P; Yang Z
Curr Pharm Biotechnol; 2015; 16(4):313-21. PubMed ID: 25601599
[TBL] [Abstract][Full Text] [Related]
31. Understanding the interfacial properties of nanostructured liquid crystalline materials for surface-specific delivery applications.
Dong YD; Larson I; Barnes TJ; Prestidge CA; Allen S; Chen X; Roberts CJ; Boyd BJ
Langmuir; 2012 Sep; 28(37):13485-95. PubMed ID: 22889049
[TBL] [Abstract][Full Text] [Related]
32. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines.
Rizwan SB; Assmus D; Boehnke A; Hanley T; Boyd BJ; Rades T; Hook S
Eur J Pharm Biopharm; 2011 Sep; 79(1):15-22. PubMed ID: 21237267
[TBL] [Abstract][Full Text] [Related]
33. Vesicular approach of cubosomes, its components, preparation techniques, evaluation and their appraisal for targeting cancer cells.
Iqbal S; Zaman M; Waqar MA; Sarwar HS; Jamshaid M
J Liposome Res; 2024 Jun; 34(2):368-384. PubMed ID: 37873797
[TBL] [Abstract][Full Text] [Related]
34. Cubosomes: An Emerging and Promising Drug Delivery System for Enhancing Cancer Therapy.
Singh S; Sachan K; Verma S; Singh N; Singh PK
Curr Pharm Biotechnol; 2024; 25(6):757-771. PubMed ID: 37929730
[TBL] [Abstract][Full Text] [Related]
35. Non-lamellar lipid liquid crystalline structures at interfaces.
Chang DP; Barauskas J; Dabkowska AP; Wadsäter M; Tiberg F; Nylander T
Adv Colloid Interface Sci; 2015 Aug; 222():135-47. PubMed ID: 25435157
[TBL] [Abstract][Full Text] [Related]
36. Formation of particulate lipid lyotropic liquid crystalline nanocarriers using a microfluidic platform.
Yu H; Dyett BP; Zhai J; Strachan JB; Drummond CJ; Conn CE
J Colloid Interface Sci; 2023 Mar; 634():279-289. PubMed ID: 36542965
[TBL] [Abstract][Full Text] [Related]
37. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.
Nguyen TH; Hanley T; Porter CJ; Boyd BJ
J Control Release; 2011 Jul; 153(2):180-6. PubMed ID: 21497623
[TBL] [Abstract][Full Text] [Related]
38. Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases.
Zabara A; Mezzenga R
J Control Release; 2014 Aug; 188():31-43. PubMed ID: 24910192
[TBL] [Abstract][Full Text] [Related]
39. Direct visualization of dispersed lipid bicontinuous cubic phases by cryo-electron tomography.
Demurtas D; Guichard P; Martiel I; Mezzenga R; Hébert C; Sagalowicz L
Nat Commun; 2015 Nov; 6():8915. PubMed ID: 26573367
[TBL] [Abstract][Full Text] [Related]
40. Lipid-PEG conjugates sterically stabilize and reduce the toxicity of phytantriol-based lyotropic liquid crystalline nanoparticles.
Zhai J; Hinton TM; Waddington LJ; Fong C; Tran N; Mulet X; Drummond CJ; Muir BW
Langmuir; 2015 Oct; 31(39):10871-80. PubMed ID: 26362479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
